We are happy to welcome three new members to the board of Oslo Cancer Cluster. Find out what they had to say about entering their new positions.
Author Archive for: Sofia Lindén
About Sofia Lindén
Sofia Lindén is responsible for producing the content for digital communications in the cluster, including articles, photographs and videos for the websites and social media platforms.
She has previously worked at the Nordic publishing company Orage as Swedish Print Editor and Digital Project Manager. She also holds a master degree in International Journalism from City University London. Find out more about Sofia by visiting her LinkedIn.
Entries by Sofia Lindén
The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma.
Oslo Cancer Cluster and its international partners organised the International Cancer Cluster Showcase (ICCS) on 3 June in Philadelphia.
Oslo Cancer Cluster member Ultimovacs entered the Oslo Stock Exchange on Monday 3 June 2019.
Nordic Nanovector raises NOK 225 million in private placements, has Phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company.
Biobanks – the powerful tools in cancer research you may have never heard of.
We asked four MBA students from Cambridge University to evaluate how patient recruitment practices in Norway can be improved.
Why are legal services an important part of Oslo Cancer Cluster? We asked Andrew Wright from Potter Clarkson to explain why they became a member.
Oslo Cancer Cluster proudly presents the new members who have joined our organisation during the first quarter of 2019.
A second group of patients have been added to an ongoing phase II clinical study of a drug combination to treat lung cancer.
How can the voices of cancer patients be heard when evaluating new methods of treatment?
The laboratories at Oslo Cancer Cluster Incubator are expanding to meet increasing demand from members.
Dr. Jon Amund Kyte at Oslo University Hospital aims to bring more and better clinical trials to Norway.
Targovax, one of the members of Oslo Cancer Cluster, has begun an expansion patient group in the clinical trial of a drug to treat skin cancer. The company Targovax is developing immune activators to target solid tumours that are difficult to treat. The drug in question, called ONCOS-102, is aimed at patients with malignant melanoma (skin […]
Vaccibody and Roche have started a new collaboration to investigate a drug combination for patients with advanced cervical cancer.
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.